DBM-1152A Inhalation Solution in Chinese Healthy Subjects

Prior treatment

• Lower respiratory tract infection within 6 weeks prior to screening, or clinically significant upper respiratory tract disease within 2 weeks prior to screening.
• Surgery within 3 months prior to screening, especially procedures affecting drug absorption, distribution, metabolism, or excretion; or planned surgery during the study.
• History of drug abuse or drug dependence within 12 months prior to screening.
• Positive drug screening (morphine, methamphetamine, ketamine, MDMA, or THC) prior to enrollment.
• Excessive consumption of tea, coffee, or caffeinated beverages (≥8 cups/day, 250mL/cup) within the past 6 months; or consumption of caffeine-rich or grapefruit-rich food/beverages within 48 hours prior to screening.
• History of alcohol abuse within the past 12 months (Male ≥ 28 units/week, Female ≥ 21 units/week); or regular drinking (≥14 units/week) within 6 months prior to screening; or inability to abstain from alcohol during the study.
• Positive breath alcohol test (\> 0 mg/100 mL) prior to enrollment.
• Positive nicotine test prior to enrollment.
• Use of any medications (including prescription, OTC, vitamins, herbal medicine, supplements, or vaccines) within 30 days prior to screening.
• Participation in any clinical trial of a drug or device within 3 months prior to screening.
• Blood donation or significant blood loss (\> 400 mL) within 3 months prior to screening; or planned blood donation during or within 3 months after the study.
• Strenuous exercise within 48 hours prior to screening.
• Pregnant or lactating women, or women planning pregnancy; use of long-acting estrogen/progestogen injections or implants within 6 months prior to screening; or positive pregnancy test.

Other illness

• Positive results in virology screening (HBsAg, anti-HCV, anti-HIV, or TP-Ab).
• Current acute or chronic oral or pharyngeal diseases (e.g., oral ulcers, pharyngitis).
• History or presence of chronic or severe diseases in the endocrine, urinary, digestive, hematological, respiratory, cardiovascular, neuropsychiatric, or immune systems, or any other physiological condition that may interfere with the study results.
• History or presence of glaucoma, functional constipation, prostatic hyperplasia, urinary tract obstruction, urinary retention, epilepsy, hyperthyroidism, paradoxical bronchospasm, diabetes, or ketoacidosis.
• Suspected allergy to DBM-1152A or its excipients; history of hypersensitivity to other anticholinergic drugs or β2-agonists; or history of significant food or drug allergies.
• Current smoker or history of smoking.
• History of needle syncope or blood syncope.
• Any other condition that, in the investigator's opinion, makes the subject unsuitable for enrollment.

Lab values

• Clinically significant abnormalities in 12-lead ECG, or corrected QT interval (QTc): Male ≥ 450 ms, Female ≥ 470 ms.
• Electrolyte or glucose abnormalities at screening: Hyperkalemia, hypokalemia, hypermagnesemia, hypomagnesemia, hypercalcemia, hypocalcemia, or hyperglycemia.
• History or presence of Short QT Syndrome or Long QT Syndrome.

Other

• Clinically significant abnormalities in physical examination, chest X-ray, hematology, urinalysis, blood biochemistry, coagulation function, thyroid function, or ophthalmic examination during screening; or FEV1/FVC \< 80% in pulmonary function tests.
• Abnormal vital signs at screening: Sitting systolic blood pressure \< 90 mmHg or ≥ 140 mmHg, diastolic blood pressure \< 55 mmHg or ≥ 90 mmHg; Pulse \< 50 bpm or \> 90 bpm; Body temperature \< 35.9°C or \> 37.6°C; Respiratory rate \< 12 breaths/min or \> 20 breaths/min.
• Difficulty in venous blood collection or inability to tolerate venipuncture.
• Inability to tolerate inhalation administration.
• Male subjects (or their partners) or female subjects planning pregnancy, sperm donation, or egg donation within 6 months after the study, or unwilling to use contraception.
• Special dietary requirements or inability to comply with the standardized diet.
• Poor compliance.

• Chinese healthy male or female subjects.
• Age 18 to 45 years (inclusive).
• Body weight: Male ≥50.0kg, Female≥45.0 kg; BMI within the range of 19.0 to 26.0 kg/m\^2 (inclusive).
• Subjects (including their partners) are willing to use effective contraception from the screening period until 6 months after the last dose.
• Subjects must fully understand the study, participate voluntarily, and sign the written informed consent.